Opthea to Host Investor Days in New York and Australia

OPT 01.08.2025

Full Press ReleaseSEC FilingsOur OPT Tweets

About Gravity Analytica

Recent News

  • 02.05.2025 - Opthea Investor Day - Melbourne
  • 02.03.2025 - Opthea Investor Day - Sydney
  • 01.28.2025 - Opthea Investor Day - New York City

Recent Filings

  • 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 01.13.2025 - EX-99.1 EX-99.1

Updates oncommercial insights and readiness plans for sozinibercept in wet AMD

Optheamanagement to present inNew York CityonTuesday, January 28at1:30 PM ET

In-person events inSydneyonFebruary 3andMelbourneonFebruary 5

MELBOURNE, AustraliaandPRINCETON, N.J.,Jan. 08, 2025(GLOBE NEWSWIRE) --Opthea Limited(ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it will host an Investor Day onTuesday, January 28, 2025at1:30 PM ETinNew York City, followed by presentations inSydneyandMelbournein early February.

As the Company prepares for the anticipated topline data readout of its two pivotal trials, COAST in early CY Q2 2025 and ShORe in mid-CY 2025, theNew Yorkin-person event and live webcast will feature presentations from international retina thought leaderCharles C. Wykoff, MD, PhDand Opthea’s senior management team, including Chief Commercial OfficerMike Campbell.Opthea’s Investor Day will highlight the following:

  • The continued medical need for better vision outcomes in wet AMD and the opportunity for sozinibercept to transform patient lives with superior vision gains.
  • New insights on the commercial potential and commercial readiness plans for sozinibercept in combination with standard-of-care anti-VEGF-A therapies.

It is expected that the presentations, followed by a question-and-answer session, will conclude by approximately3:00 PM ET. Following the live webcast, a replay will be made available on the Company’s website.

The Company’s senior management will also host in-person investor presentations inSydneyonMonday February 3at4:30 PMAEDT andMelbourneonWednesday February 5at4:30 PMAEDT.

Links to register or access the webcast will be available on the Investor Section of the Company’s website under “Events and Presentations”here.

AboutCharles C. Wykoff, MD, PhD

Charles C. Wykoff, MD, PhD is a board-certified retina specialist withRetina Consultants of Texas(RCTX). Leading a top international research facility for vitreoretinal diseases,Dr. Wykoffserves as Director of Research at RCTX and is Chair of Research and Clinical Trials atRetina Consultants of America. In addition, he serves as the elected Deputy Chair of Ophthalmology for theBlanton Eye Institute,Houston Methodist Hospital, and Clinical Professor of Ophthalmology,Weill Cornell Medical College.Dr. Wykoffhas been awarded multiple Achievement, Honor and SeniorHonor Awardsand has published over 350 peer-reviewed manuscripts.Dr. Wykoffserves as the Chief Investigator for Opthea’s COAST Phase 3 pivotal trial and is Co-Chair of the COAST andShORe Steering Committee.

AboutMike Campbell, Chief Commercial Officer,Opthea

Mr. Campbellbrings 30 years of biotech and pharmaceutical commercial leadership experience across sales, marketing, market access, patient services, and operations to the Company. He dedicated most of his career to launching and commercializing innovative treatments for retinal and ocular surface diseases. During his tenure atGenentech,Mr. Campbellwas a key leader for the commercial build and launch of Lucentis®, the first anti-VEGF-A treatment approved for wet AMD; he served in commercial leadership roles through the lifecycle of Lucentis®,including the expansion into Diabetic Macula Edema, and Retinal Vein Occlusion. He also contributed to the pre-launch commercial planning of Beovu®in wet AMD at Novartis, as well as the$3.4 billiondivestiture of Xiidra®for Dry Eye Disease to Novartis, during his tenure at Shire.Mr. Campbellmost recently served as Senior Vice President and Head of Commercial at Viatris Eye Care which acquiredOyster Point Pharma, where he led the commercial build for the launch of Tyrvaya®in Dry Eye Disease. Mr. Campbell holds a Bachelor of Science degree fromAuburn Universityand is an Executive Education graduate from theUniversity of Pennsylvania,Wharton School of Business.

AboutOpthea

Opthea(ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,NCT04757636, and ShORe,NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website atwww.opthea.comand follow us onXandLinkedIn.

Authorized for release to ASX byFrederic Guerard, PharmD, CEO

Investor InquiriesPJ KelleherLifeSci Advisors, LLCEmail:pkelleher@lifesciadvisors.comPhone: 617-430-7579Media InquiriesSilvana Guerci-LenaNorthStream Global PartnersEmail:silvana@nsgpllc.com

Join our email database to receive program updates:Tel: +61 (0) 3 9826 0399, Email:info@opthea.comWeb:www.opthea.com

Source:Opthea Limited

Primary Logo

Source: Opthea Limited

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com